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Apatient was seen in consultation for intoler-ance to multiple antihypertensive medica-
tions. She presented a list of her experiences,
which is summarized in the Table. Although the
cough she experienced while taking angiotensin-
converting enzyme inhibitors was a typical side
effect of this drug class and consistent on rechal-
lenge, this was not the case with her other
reported medication reactions. When the patient
received the same medication labeled in the same
way (Calan SR), she had diarrhea on both
occasions. When she received the same medica-
tion labeled differently (Calan SR or Verelan and
Cozaar or Hyzaar), her reactions differed. The
patient listed valsartan, propranolol, hydralazine,
and indapamide as ineffective, but it was not
clarified whether they were tolerated.
The patient was taking one-fourth 100 mg meto-
prolol twice a day, but experienced headache and
heartburn at higher doses, and clonidine 0.1 mg
daily, but experienced a localized rash at higher
doses. She had been hospitalized on one occasion
for hypertension and on another occasion for
hypertension and ‘‘stress.’’ She was currently taking
alprazolam. She summarized her view of antihyper-
tensive medications as ‘‘I am scared of them.’’ She
added that statins raised her blood pressure, but
she was tolerating levothyroxine.
After an explanation for the origin of these non-
specific side effects was provided to the patient, she
stated that she did not believe this accounted for
her reactions.
DISCUSSION
Physicians and patients are familiar with the pla-
cebo effect, an improvement mediated by an inert
treatment believed to be beneficial. The less well-
known nocebo response is the opposite, a worsen-
ing mediated by an inert treatment believed to be
harmful. The literature sometimes considers adverse
effects in placebo-treated patients as nocebo
responses, but the belief that the treatment is
harmful should be required. This patient’s case pro-
vides an excellent example of nocebo responses.
Although this phenomenon accounts for a signifi-
cant fraction of unusual reactions to antihyperten-
sive medications and of hypertension clinic referrals
for medication intolerance, the term has not been
mentioned in the hypertension literature to the best
of our knowledge.
Barsky and coworkers1 reviewed the relationship
between the nocebo phenomenon and nonspecific
medication side effects, which they characterize as
unexplainable by pharmacology, idiosyncratic, and
not dose-dependent. They point out that symptoms
(eg, fatigue, difficulty concentrating, drowsiness ⁄
somnolence, headache, dizziness, weakness, nausea ⁄
gastrointestinal complaints) are common in healthy
persons without medications or in placebo recipi-
ents in clinical trials of asymptomatic diseases and
that these symptoms may be misattributed to a
drug. Barsky and associates mention the role of
negative expectations and suggestions, conditioning,
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and underlying psychological characteristics (anxi-
ety, depression, and somatization) as important fac-
tors in producing nonspecific side effects.
The impact of psychiatric comorbidity on hyper-
tension management was recently reviewed in this
journal.2 Misattribution of the symptoms of anxiety
to medication adverse effects and reluctance to start
medications viewed as potentially toxic were men-
tioned. A large study analyzing medication intoler-
ance in a hypertension clinic found that about half
of the episodes of intolerance due to symptoms
were judged to be nonspecific.3 These were associ-
ated with panic attacks, anxiety, and depression,
whereas specific intolerances were not.
Although psychiatric comorbidity is strongly
associated with nocebo responses, negative expecta-
tion and suggestion produce nocebo responses in
volunteers and medical patients. Flaten and col-
leagues4 gave a muscle relaxant and placebo to
healthy volunteers, telling some they were getting
a stimulant, others a relaxant, and others no
information. Suggestion that participants were get-
ting a stimulant increased reported tension. Silvestri
and associates5 reported that patients with hyper-
tension who received atenolol had more erectile
dysfunction if they were told that erectile dysfunc-
tion could occur but was uncommon than if they
were not even told the name of the medication.
Patients told only the name of the medication had
an intermediate frequency of erectile dysfunction.
Patients reporting erectile dysfunction were treated
with sildenafil and placebo in a crossover study and
described equivalent efficacy with the exception of
one patient.
Negative expectations appear capable of produc-
ing a wide range of effects. Reeves and colleagues6
describe a patient in a placebo-controlled, blinded
antidepressant drug trial who overdosed on 29 pla-
cebo capsules believing that they contained a new
experimental drug; hypotension developed that
required intravenous fluids. When told he had
taken a placebo, this abated. Benson7 discusses
Table. List of Adverse Drug Experiences in This Case
Class Drug Adverse Effect
ACE inhibitor Enalapril ⁄ HCTZ Cough
Lisinopril Cough, heartburn
Lisinopril ⁄ HCTZ Cough
Quinapril Cough
Aldosterone blocker Spironolactone Diarrhea
a-Blocker Doxazosin Head hurt, nervous
Prazosin Felt bad
Terazosin Blurry, very dry eyes
a ⁄ b-Blocker Labetalol Head, neck hurt
ARB Candesartan Head, neck, chest, back hurt
Irbesartan Bad heartburn
Losartan Heartburn




Betaxalol Red, sore gums
Metoprolol Head hurt, heartburn
Penbutolol Really tired, eyes watered
Calcium channel blocker Amlodipine Stomach hurt, heartburn
Diltiazem Eyes watered
Isradipine Head, neck, chest, back hurt
Nisoldipine Neck, chest, back hurt
Verapamil (brand 1) Diarrhea
Verapamil (brand 2) Shoulders, back, neck hurt
Central a agonist Clonidine (oral) Rash
Methyldopa Head, ears felt like bursting
Diuretic HCTZ ⁄ triamterene Stomach hurt, diarrhea
Renin inhibitor Aliskiren Felt horrible
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; HCTZ, hydrochlorothiazide.
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voodoo death, sudden death, and surgical mortality
as responses to negative expectations. Hahn8 men-
tions heart attacks and cardiovascular mortality,
epidemic hysteria (globus ⁄cough ⁄ laryngismus,
abnormal movements, fainting, nausea, abdominal
malaise, and headaches), asthma attacks, psycho-
genic seizures, and allergic reactions as responses to
negative expectations.
The patient described here illustrates many of the
issues relating to nocebo responses in patients with
hypertension. Patients may exhibit typical adverse
reactions combined with their nocebo responses.
Patients may tolerate medications for other condi-
tions or some antihypertensive medications, but at
low doses. They may respond differently to the
same medicine when labeled differently. This may
contribute to reports of adverse responses specific to
generic drugs. Many patients do not remain on a
drug producing symptoms long enough to evaluate
efficacy, but a lack of blood pressure lowering, and
especially an increase in blood pressure, may reflect
a response to the symptoms, rather than a lack of
efficacy. This patient’s increased blood pressure on
statin therapy is an example.
Although recognizing nocebo responses is not
difficult, especially by the time a patient is referred
to a specialist for nonspecific reactions to multiple
medications, the most effective approach to caring
for these patients remains to be defined. Barsky and
coworkers1 suggest providing an explanation of the
side effects and helping patients reattribute them to
the patients’ disease(s) or emotions or normal phys-
iology. However, many patients with nocebo
responses are not simply attributing preexisting
symptoms or new coincidental symptoms to their
medication. Often, patients acknowledge that the
nocebo response may be a reasonable explanation
of reactions in other patients, but not in them.
Barsky and associates also suggest using collabora-
tive strategies for prescribing; some of these patients
are willing to experiment with low doses of well-
tolerated medications, especially if this approach
has not previously been explored. Emphasizing the
importance of lifestyle changes is especially impor-
tant. Further research on recognizing and managing
nocebo responses is important, as they may be an
important contributor to suboptimal blood pressure
control.
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